TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
BPOM declares suspended AstraZeneca vaccine batch safe to use
In a press statement, the Drug and Food Monitoring Agency (BPOM) concluded that the vaccine batch "meets quality requirements and is safe to use."
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
A photo taken on March 22, 2021 shows vials of AstraZeneca COVID-19 vaccine before being inoculated to residents of Jombang regency, East Java. President Joko (Antara/Syaiful Arif)
T
he government declared Thursday that a batch of AstraZeneca Plc's coronavirus vaccine, suspended earlier this month following the death of a 22-year-old man a day after his inoculation with the vaccine, is safe to use.
In a press statement, the Drug and Food Monitoring Agency (BPOM) concluded that the vaccine batch "meets quality requirements and is safe to use."
The conclusion, the agency said, was made based on the results of sterility and toxicity tests it conducted, during which it found "there was no correlation between the quality of the AstraZeneca vaccine batch and the reported side effects."
“According to test results, it can be concluded that there was no relation between the quality of COVID-19 vaccine batch number CTMAV547 with the post immunization event reported,” said BPOM.
The Health Ministry suspended the distribution and use of the batch on May 16 after local media reported that the man received a jab from the batch in the capital Jakarta on May 5 and died the next day.
The batch in question, consisting of about 450,000 doses, arrived last month. It had earlier been distributed to Jakarta and North Sulawesi Province in central Indonesia and the military.
It is part of the 3,852,000 AstraZeneca doses the Indonesian government has received through the World Health Organization-backed COVAX facility.
COVAX is an international vaccine distribution platform set up to ensure equitable access to shots for developing countries.
Indonesia has fully inoculated almost 10.2 million of its 187 million eligible citizens under a nationwide vaccination drive that started in mid-January.
